Nvidia’s results, Indian tariffs, French markets - what’s moving markets
Investing.com - Jefferies initiated coverage on Shoulder Innovations (NYSE:SI) with a Buy rating and a $19.00 price target on Monday. The stock, currently trading at $12.71, has experienced recent headwinds with an 11.3% decline over the past week. With a market capitalization of $281 million, InvestingPro data shows the company maintains strong liquidity with a current ratio of 7.1.
The price target represents approximately 5 times the company’s estimated 2026 sales, according to Jefferies’ research note.
Jefferies believes Shoulder Innovations is gaining market share in the large and growing shoulder market, supported by superior clinical data and differentiated implants.
The firm highlighted the company’s surgical instrument planning and efficiency advantages as key factors giving it "the right to win" against competitors.
Jefferies projects Shoulder Innovations can achieve more than 30% compound annual growth rate through 2028 as it takes market share from incumbent companies, with additional growth opportunities in the future.
In other recent news, Goldman Sachs has initiated coverage on Shoulder Innovations with a Buy rating. The investment bank has set a price target of $20.00 for the company’s stock. Goldman Sachs highlighted the company’s revenue growth trajectory and its position in an attractive end-market as key factors for its positive outlook. The bank also noted that Shoulder Innovations compares favorably to small to mid-cap medical technology companies. These developments indicate a meaningful upside to the current valuation of Shoulder Innovations, according to Goldman Sachs. The analyst firm’s assessment provides investors with insights into the company’s potential growth and market position. These recent developments could be of interest to investors considering the company’s future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.